Arthrosi Therapeutics is developing AR882, a proprietary drug candidate that significantly lowers serum urate levels in patients with gout and tophaceous gout. The company addresses the inadequacy of current treatments by providing a targeted therapy that aims to reduce painful flares and tophi formation in this underserved patient population.
Funding
$145.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many of the nine million patients in the US living with gout are undertreated, relying on short-term or sub-optimal treatments that don’t fully address their needs. Current therapies often fail to adequately lower serum urate levels, leading to painful flares and the formation of tophi (urate crystal deposits) in patients with gout and tophaceous gout.
Solution
Arthrosi Therapeutics is developing AR882, a proprietary drug candidate designed to significantly lower serum urate levels in patients with gout, including those with tophaceous gout and chronic kidney disease. AR882 offers a targeted therapeutic approach to reduce the frequency and severity of gout flares, as well as tophi formation. The company aims to provide a more effective long-term solution for managing gout and improving the quality of life for patients who are not adequately helped by existing treatments.
Target Audience
The primary target audience includes individuals suffering from gout and tophaceous gout, particularly those who are undertreated or do not respond adequately to existing therapies.
Features
- AR882: A novel drug candidate specifically designed to lower serum urate levels.
- Potential to reduce both the frequency and severity of gout flares.
- Designed to address tophi formation, a common complication of poorly managed gout.
- May be suitable for gout patients with impaired renal function.
- Currently undergoing Phase 3 clinical trials (REDUCE 2).
- Granted Fast Track Designation by the FDA for tophaceous gout.